Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab adjunctive therapy versus placebo in severe uncontrolled eosinophilic asthma
2020-003632-25Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and eosinophilic asthma (EA) comparing Depemokimab adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Annualized rate of clinically significant exacerbations over 52 weeks. Started Feb 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2020-003632-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003632-25.